INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a recently-discovered infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that has quickly become a global pandemic. As of the writing of this report, more than 3 million cases and nearly 250 000 deaths have been documented. However, the epidemiology of the disease is still being studied, and much more information is required to establish adequate measures for its prevention and control, especially among patients vulnerable to severe disease (pneumonia) or death [1].

Several studies have demonstrated higher frequencies of severe cases and mortality among COVID-19 patients with underlying comorbidities, such as diabetes, high blood pressure (HBP), obesity, and cardiovascular disease (CVD), relative to patients without comorbidities [2,3]. Although the causal mechanisms by which chronic conditions increase the risk of COVID-19 severity and mortality are still being studied, it has been postulated that patients with HBP and diabetes have an increased susceptibility of severe SARS-CoV-2 infection [4,5]. It has also been proposed that SARS-CoV-2 infection may cause or worsen endotheliitis, which can further affect the condition of people with previous endothelial dysfunction, such as those with obesity, diabetes, HBP, and other CVDs [5]. This raises the question of how multimorbidity—the presence of 2 or more chronic comorbidities—may influence disease severity and mortality in patients with SARS-CoV-2 infection.

Mexico has one of the highest COVID-19 mortality rates among Latin American countries. As of May 18, 2020, more than 20 000 confirmed cases and 2154 deaths attributed to COVID-19 had been reported in Mexico [1]. The potential associations of multimorbidity with disease severity and mortality in COVID-19 patients have received special attention in Mexico, as it is one of the Latin American countries with the highest prevalence of chronic conditions; 19.0-25.5% of Mexican adults have HBP, 10.0% have diabetes, and 28.0% are obese [6,7]. To date, only 1 peer-reviewed study, conducted in China, has reported a higher combined risk of admission to intensive care, intubation, or death in patients with multimorbidity compared to those without multimorbidity [8]. However, this association has not been studied in Latin America, and pneumonia and death have not been considered as separate outcomes.

The epidemiological surveillance system of the Secretaría de Salud de México collects information regarding the characteristics and comorbidities of diagnosed COVID-19 cases, as well as their clinical course and outcomes. The government of Mexico has released these data. In this study, we aimed to identify the chronic conditions and multimorbidity patterns present among COVID-19 patients and to examine their associations with pneumonia and death. Our results could help facilitate better understanding and decision-making regarding the identification of groups at relatively high risk of severe illness and death due to COVID-19 and the implementation of preventative measures affecting these groups.

METHODS

Study Design and Data Source

A cross-sectional study was performed to analyze the publicly available data of patients with COVID-19 diagnosed via reverse transcription-polymerase chain reaction (RT-PCR). These data were released by the Secretaría de Salud de México and covered the period ending on May 18, 2020. Socio-demographic and medical data (regarding date of disease onset, disease duration, epidemiological profile, presence of chronic conditions, molecular diagnostic test result, and vital status), were collected by physicians using an epidemiological COVID-19 case report form in suspected COVID-19 patients. These data were systematized using an epidemiological surveillance system and are available at https://www.gob.mx/salud/documentos/datos-abiertos-152127.

Study Variables

The dependent variables were pneumonia and death in patients with COVID-19. Eight comorbidities were included as independent variables: HBP, diabetes, obesity, asthma, immunosuppression, other CVDs, chronic obstructive pulmonary disease (COPD), and chronic kidney disease. The chronic conditions included in the analysis corresponded to the conditions reported as associated with COVID-19 in the literature [9-15] and the availability of the relevant information in the patient data. A simple count of the 8 comorbidities was used to classify participants into 4 categories: no comorbidity, 1 comorbidity, 2 comorbidities, or 3 or more comorbidities. Likewise, the 3 most frequent comorbidities (HBP, diabetes, and obesity) were classified into dyads. The presence of ≥2 of the 8 reported comorbidities was considered to indicate multimorbidity.

Statistical Analysis

The variables of interest were presented as frequencies and percentages for the categorical variables and as means and standard deviations for the continuous variables. The frequencies of pneumonia and death were presented according to the characteristics and comorbidities evaluated and stratified by sex. Simple logistic regression models were applied to measure the associations of the independent variables with pneumonia and death in patients with COVID-19. The chronic conditions that were found to be associated with pneumonia or death (p<0.05) in the simple logistic regression analysis were included in two adjusted logistic regression models. The covariables included in the adjusted models were age (continuous), gender (men/women), and smoking status (yes/no). The results were expressed as odds ratios (ORs) and adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for both models. Based on the adjusted models, the marginal effects were estimated along with their 95% CI, and the probabilities of pneumonia and death according to the number of comorbidities for each year of age were graphed.

Statistical analysis was performed using Stata version 14 (StataCorp., College Station, TX, USA). For all analyses, a p-value <0.05 was considered statistically significant.

Ethics Statement

As an analysis of secondary data, this study did not require the approval of an institutional ethics committee. The data are publicly available on the platform of the Secretaría de Salud de México under the Mexican open data policy intended to facilitate the access, use, reuse, and redistribution of information.

RESULTS

Complete data regarding the study variables were available for 51 053 patients with COVID-19, and these patients were included in the analysis. A total of 580 patients were excluded due to incomplete data. Of the included patients, 29 422 were men (57.6%). The overall mean age was 46.6±15.8 years (men, 47.1±15.7 years; women, 45.8±16.0 years). The mean disease duration was 4.2±3.3 days. A total of 14 684 (28.8%) patients presented with pneumonia (men, 32.5%; women, 23.7%).

Regarding the presence of chronic conditions, 27 667 (54.2%) of the participants had no comorbidities, while 13 652 (26.7%) presented 1 chronic condition. Multimorbidity was present in 9734 (19.1%) of the patients, with the presence of 2 (n=6518, 12.8%) and 3 (n=2490, 4.9%) comorbidities being the most common. The largest number of simultaneous chronic conditions was 8 (14 patients) (Table 1).

The results included 5233 (10.3%) deaths (men, 12.1%; women, 7.7%), with a mean time from disease onset to death of 10.6±6.5 days (Table 1). Regarding age group, pneumonia was reported in more than 50% of the people in the 65-74 (50.3%), 75-84 (53.7%), and 85 or older (51.4%) age groups, while the greatest frequencies of death were found in the 65- 74 (27.1%), 75-84 (29.1%), and 85 or older (31.3%) age groups (Table 2). In the adjusted logistic regression model, across the entire study population, it was found that chronic conditions such as HBP, diabetes, obesity, immunosuppression, other CVDs, COPD, and chronic kidney disease were associated with an increased risk of pneumonia. In men, other CVDs and COPD were not found to be associated with pneumonia. Likewise, across the study population, chronic conditions such as HBP, diabetes, obesity, immunosuppression, other CVDs, COPD, and chronic kidney disease were associated with an increased probability of death (Table 3).

A significant incremental gradient was observed for the association between multimorbidity and pneumonia in the general population (p<0.001), with the presence of 1 (aOR, 1.68; 95% CI, 1.60 to 1.77), 2 (aOR, 2.07; 95% CI, 1.95 to 2.20), and 3 or more chronic conditions (aOR, 2.40; 95% CI, 2.22 to 2.60) associated with a progressively increasing probability of this outcome. Likewise, across the study population, a significant incremental gradient (p<0.001) was found for the relationship between multimorbidity and death, in which the presence of 1 (aOR, 1.89; 95% CI, 1.75 to 2.04), 2 (aOR, 2.51; 95% CI, 2.30 to 2.73), and 3 or more chronic conditions (aOR, 3.49; 95% CI, 3.15 to 3.86) were associated with an increased probability of death among the patients. These gradients demonstrating higher probabilities of pneumonia and death in patients with more chronic conditions were also present in both men and women and were statistically significant (Table 4).

Figure 1 shows the marginal effects of age and number of comorbidities on the probabilities of pneumonia and death. The probabilities of both pneumonia and death increased with the number of comorbidities and age.

DISCUSSION

In this study, we sought to identify patterns of chronic conditions and multimorbidity and to evaluate their associations with pneumonia and death in Mexican patients with COVID-19. Chronic conditions such as HBP, diabetes, obesity, other CVDs, and chronic kidney disease were found to increase the likelihood of pneumonia. Likewise, HBP, diabetes, obesity, immunosuppression, COPD, and chronic kidney disease increased the probability of death in patients with COVID-19. Regarding multimorbidity, a greater number of chronic conditions was found to be associated with an increased probability of death or pneumonia among the study sample.

In the present study, an association was found between chronic conditions and pneumonia in patients with COVID-19. An early report from Wuhan, China, noted that about half of a sample of patients who were hospitalized for SARS-CoV-2 pneumonia had an additional medical condition. The most common comorbidities were HBP, diabetes, CVDs, and malignancies, which (except for malignancies) coincide with the most frequent conditions found in the Mexican population with COVID-19. Likewise, in the study from Wuhan, these conditions were associated with the presence of pneumonia [2]. Furthermore, the Centers for Disease Control and Prevention in the United States reported that people with serious medical conditions such as asthma (moderate to severe), COPD, diabetes, CVDs, kidney diseases, severe obesity, immunosuppression, and liver diseases have a greater probability of developing severe forms of COVID-19, including pneumonia [15]. It has been postulated that the development and severity of pneumonia may be influenced by the use of antihypertensive medication, commonly prescribed to patients with HBP and diabetes. These medications may lead to elevated lung tissue concentrations of angiotensin-converting enzyme 2, which acts as the receptor for the entry of SARS-CoV-2 [16,17]. However, other authors have reported that elevated angiotensinconverting enzyme 2 levels are not associated with an increased risk of pneumonia [18]. This suggests the need for further study of the influence of chronic conditions on the development of COVID-19.

Regarding multimorbidity and pneumonia in patients with COVID-19, the probability of developing pneumonia was found to increase as the number of chronic conditions increased. COVID-19 patients with comorbidities have been reported to exhibit a worse response to treatment than patients without comorbidities [19]. HBP and respiratory and CVDs are associated with a relatively severe presentation of COVID-19, including the development of pneumonia [20-22]. Likewise, greater patient age is associated with the development of pneumonia and the severe presentation of COVID-19 [23]. The presence of multimorbidity among adults (particularly older adults) impacts the physical and mental health of this group, particularly in lowincome and middle-income countries [24]. This affects the response capacity to treatment in these patients.

An association was found between the presence of chronic conditions and death in patients with COVID-19. In China, a higher frequency of COVID-19 infection and a greater lethality of the disease have been reported among patients with HBP [4,13,20,24]. Diabetes has also been described as one of the most common chronic conditions in patients with COVID-19, especially among those in the intensive care unit or with severe forms of the disease [12,19,25]. Obesity is another chronic condition associated with increased mortality risk due to challenges in the management of obese patients in relation to positioning, mobilization, and intubation [26,27]. Regarding immunosuppression, the host immunological response to SARSCoV-2 infection and its relationship with the pathophysiology and prognosis of the disease is still under study [28,29]. It has been reported that patients with COPD have an increased risk of developing severe forms of illness, possibly due to alterations in the inflammatory response, immunological and microbiome imbalances, and the use of corticosteroids, among other factors [30]. Chronic kidney disease has also been described as a chronic condition associated with a greater risk of severe manifestation of COVID-19 and death [8,31,32].

With respect to the relationship between multimorbidity and death in patients with COVID-19, an incrementally higher probability of death was observed among patients with more chronic conditions. The prevalence of multimorbidity increases with age [33]. In addition, it has been reported that older adults who have 2 or more comorbidities have a higher mortality rate than adults who do not [33,34]. The case series on COVID-19 published to date describe greater disease severity and a higher risk of death among older patients, particularly the most elderly [11,14]. In Mexico, the presence of multimorbidity in adults has been described as a predictor of quality of life and all-cause mortality [35]. Mexico has a significant burden of disease due to chronic diseases; in 2016, 80% of deaths were attributable to chronic conditions [6]. This high rate of deaths due to chronic diseases corresponds to the high prevalence of chronic conditions in the Mexican population, among which 25.5% of individuals have HBP [7], and 28% of adults are obese [6]. Given that multimorbidity can increase the risk of death due to COVID-19, in countries like Mexico, which have a high burden of disease due to these conditions, it is necessary to develop strategies to mitigate the spread of this disease in these population subgroups to decrease the impact of COVID-19 on health systems.

This study was not without limitations. The data analyzed were secondary in nature, and the accuracy of the data therefore, cannot be guaranteed. Additionally, the cases analyzed included only patients diagnosed with COVID-19 via RT-PCR, and thus, false-negative results of the RT-PCR test would not have been included in the analysis. In addition, bias may have been introduced insofar as the process of obtaining and handling of the sample influenced the results of the diagnostic test. Another possible source of bias stems from the fact that patients with asymptomatic or mildly symptomatic COVID-19 who did not seek medical attention would not have been included among the cases analyzed. Despite the limitations inherent to the information source, the use of a large dataset that includes all COVID-19 cases identified with molecular diagnostic tests and collected officially by the government of Mexico is useful for the initial study of the relationship between multimorbidity and COVID-19, bearing in mind the high burden of disease due to chronic conditions in Mexico.

In conclusion, several chronic conditions are associated with the development of pneumonia and death in Mexican patients with COVID-19. Additionally, an increase in the number of simultaneous chronic conditions was found to be associated with increased risk of pneumonia and death among these patients. These findings may be useful in the effort by decisionmakers to develop strategies to prevent COVID-19 in vulnerable subgroups, such as people with comorbidities. According to reports from different sources, patients with chronic conditions have a greater risk of COVID-19 than patients without such conditions. Hence, additional research is necessary to understand and deepen the study of the pathophysiological processes that determine this association, and this research is particularly important due to the high burden of chronic disease in various Latin American countries, including Mexico.

ACKNOWLEDGEMENTS

Notes

CONFLICT OF INTEREST

The authors have no conflicts of interest associated with the material presented in this paper.

FUNDING

None.

Notes

AUTHOR CONTRIBUTIONS

Conceptualization: AHV, DA. Data curation: AHV, RVF. Formal analysis: AHV, RVF. Funding acquisition: None. Methodology: AHV. Visualization: AHV. Writing – original draft: GBQ, DA, RVF, AHV. Writing – review & editing: GBQ, DA, RVF, AHV.

Figure. 1.

Marginal effects of age (in years) and number of comorbidities on the probabilities of (A) pneumonia or (B) death in the Mexican population with coronavirus disease 2019 (COVID-19).

REFERENCES

• 1. Coronavirus Resource Center, Johns Hopkins University. Maps & trends [cited 2020 May 1]. Available from: https://coronavirus.jhu.edu/map.html
• 2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061-1069ArticlePubMedPMCPDF
• 3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506ArticlePubMedPMC
• 4. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8(4):e21ArticlePubMedPMC
• 5. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395(10234):1417-1418ArticlePubMedPMC
• 6. World Health Organization. Noncommunicable diseases (NCD) country profiles 2018. [cited 2020 May 1]. Available from: https://apps.who.int/iris/handle/10665/274512
• 7. Nonato IC, Barrera LH, Pedroza A, Medina C, Barquera S. Hypertension in Mexican adults: prevalence, diagnosis and type of treatment. Ensanut MC 2016. Salud Publica Mex 2018;60(3):233-243. (Spanish)ArticlePubMed
• 8. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55(5):2000547ArticlePubMedPMC
• 9. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020;52(6):1193-1194ArticlePubMedPMCPDF
• 10. Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep 2020;2(3):100113ArticlePubMedPMC
• 11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-1062ArticlePubMedPMC
• 12. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care 2020;24(1):108ArticlePubMedPMCPDF
• 13. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARSCoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020;94: 91-95ArticlePubMedPMC
• 14. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368: m1091ArticlePubMedPMC
• 15. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19). [cited 2020 Apr 30]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html
• 16. Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020;43(3):219-222. (Chinese)PubMed
• 17. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020;27(3):taaa041ArticlePubMedPDF
• 18. Bravi F, Flacco ME, Carradori T, Volta CA, Cosenza G, De Togni A, et al. Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, in a sample of infected Italian citizens. PLoS One 2020;15(6):e0235248ArticlePubMedPMC
• 19. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020;ciaa270ArticlePDF
• 20. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8(5):475-481ArticlePubMedPMC
• 21. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;e200994ArticlePDF
• 22. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol 2020;55(6):327-331ArticlePubMed
• 23. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020;133(9):1032-1038ArticlePubMedPMC
• 24. Arokiasamy P, Uttamacharya U, Jain K, Biritwum RB, Yawson AE, Wu F, et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? BMC Med 2015;13: 178ArticlePubMedPMCPDF
• 25. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA 2020;323(18):1769-1770ArticlePubMedPDF
• 26. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708-1720ArticlePubMed
• 27. Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring) 2020;28(6):1005ArticlePubMed
• 28. Ryan DH, Ravussin E, Heymsfield S. COVID 19 and the patient with obesity - the editors speak out. Obesity (Silver Spring) 2020;28(5):847ArticlePubMedPMC
• 29. D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl 2020;26(6):832-834ArticlePubMed
• 30. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39(5):405-407ArticlePubMedPMC
• 31. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med 2020;167: 105941ArticlePubMedPMC
• 32. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97(5):829-838ArticlePubMedPMC
• 33. Nunes BP, Flores TR, Mielke GI, Thumé E, Facchini LA. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 2016;67: 130-138ArticlePubMed
• 34. Landi F, Liperoti R, Russo A, Capoluongo E, Barillaro C, Pahor M, et al. Disability, more than multimorbidity, was predictive of mortality among older persons aged 80 years and older. J Clin Epidemiol 2010;63(7):752-759ArticlePubMed
• 35. Rivera-Almaraz A, Manrique-Espinoza B, Ávila-Funes JA, Chatterji S, Naidoo N, Kowal P, et al. Disability, quality of life and all-cause mortality in older Mexican adults: association with multimorbidity and frailty. BMC Geriatr 2018;18(1):236ArticlePubMedPMCPDF

Figure & Data

References

Citations

Citations to this article as recorded by  

• A network-based model to assess vaccination strategies for the COVID-19 pandemic by using Bayesian optimization
  Gilberto González-Parra, Javier Villanueva-Oller, F.J. Navarro-González, Josu Ceberio, Giulia Luebben
  Chaos, Solitons & Fractals.2024; 181: 114695.     CrossRef
• Impact of COVID-19 on ‘Start Smart, Then Focus’ Antimicrobial Stewardship at One NHS Foundation Trust in England Prior to and during the Pandemic
  Rasha Abdelsalam Elshenawy, Nkiruka Umaru, Zoe Aslanpour
  COVID.2024; 4(1): 102.     CrossRef
• Multimorbidity and frailty are associated with poorer SARS-CoV-2-related outcomes: systematic review of population-based studies
  Tatjana T. Makovski, Jinane Ghattas, Stéphanie Monnier-Besnard, Lisa Cavillot, Monika Ambrožová, Barbora Vašinová, Rodrigo Feteira-Santos, Peter Bezzegh, Felipe Ponce Bollmann, James Cottam, Romana Haneef, Brecht Devleesschauwer, Niko Speybroeck, Paulo Jo
  Aging Clinical and Experimental Research.2024;[Epub]     CrossRef
• Mortalidad en adultos mexicanos de 50 a 80 años de edad con multimorbilidad en un período de observación de 18 años
  Beatriz Novak, Daniel Lozano Keymolen
  Estudios Demográficos y Urbanos.2023; 38(1): 9.     CrossRef
• Age and Comorbidities as Risk Factors for Severe COVID-19 in Mexico, before, during and after Massive Vaccination
  Lenin Domínguez-Ramírez, Francisca Sosa-Jurado, Guadalupe Díaz-Sampayo, Itzel Solis-Tejeda, Francisco Rodríguez-Pérez, Rosana Pelayo, Gerardo Santos-López, Paulina Cortes-Hernandez
  Vaccines.2023; 11(11): 1676.     CrossRef
• Study of optimal vaccination strategies for early COVID-19 pandemic using an age-structured mathematical model: A case study of the USA
  Giulia Luebben, Gilberto González-Parra, Bishop Cervantes
  Mathematical Biosciences and Engineering.2023; 20(6): 10828.     CrossRef
• HEMOGRAM INDICATORS IN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY COVID-19 DEPENDING ON THE CHARLSON COMORBIDITY INDEX
  T. M. Homeliuk, M. I. Marushchak
  Bulletin of Problems Biology and Medicine.2023; 1(1): 161.     CrossRef
• Correlates of In-Hospital COVID-19 Deaths: A Competing Risks Survival Time Analysis of Retrospective Mortality Data
  Ashish Goel, Alpana Raizada, Ananya Agrawal, Kamakshi Bansal, Saurabh Uniyal, Pratima Prasad, Anil Yadav, Asha Tyagi, RS Rautela
  Disaster Medicine and Public Health Preparedness.2022; 16(5): 1889.     CrossRef
• Inference on the Beta Type I Generalized Half Logistic Distribution under Right-Censored Observation with Application to COVID-19
  Phillip Oluwatobi Awodutire, Ethelbert Chinaka Nduka, Maxwell Azubike Ijomah, Oluwatosin Ruth Ilori, Oluwafemi Samson Balogun, Niansheng Tang
  International Journal of Mathematics and Mathematical Sciences.2022; 2022: 1.     CrossRef
• Association between chronic kidney disease and mortality in patients with a confirmed COVID-19 diagnosis
  Jacqueline Betsabe Puicón-Suárez, Sandra Zeña-Ñañez, Virgilio E. Failoc-Rojas
  PeerJ.2022; 10: e13437.     CrossRef
• The effects of hypertension on the prognosis of coronavirus disease 2019: a systematic review and meta-analysis on the interactions with age and antihypertensive treatment
  Alimamy Umaru Kabia, Ping Li, Zhichao Jin, Xiaojie Tan, Yilong Liu, Yuqi Feng, Keyao Yu, Ming Hu, Dongming Jiang, Guangwen Cao
  Journal of Hypertension.2022; 40(12): 2323.     CrossRef
• Associations of symptom combinations with in-hospital mortality of coronavirus disease-2019 patients using South Korean National data
  Suyoung Jo, Hee-kyoung Nam, Heewon Kang, Sung-il Cho, Russell Kabir
  PLOS ONE.2022; 17(8): e0273654.     CrossRef
• Epidemiological Profile and Social Welfare Index as Factors Associated with COVID-19 Hospitalization and Severity in Mexico City: A Retrospective Analysis
  Mario Antonio Téllez-González, Juan Antonio Pineda-Juárez, Juan Antonio Suárez-Cuenca, Mónica Escamilla-Tilch, Daniel Santillán-Cortez, Silvia García, Sofía Lizeth Alcaraz-Estrada, Juan Carlos Pérez-Razo, Carlos Alberto Delgado-Quintana, Joel Vargas-Herná
  International Journal of Environmental Research and Public Health.2022; 19(22): 14803.     CrossRef
• Trends of COVID-19 Admissions in an Italian Hub during the Pandemic Peak: Large Retrospective Study Focused on Older Subjects
  Andrea Ticinesi, Antonio Nouvenne, Nicoletta Cerundolo, Alberto Parise, Beatrice Prati, Angela Guerra, Tiziana Meschi
  Journal of Clinical Medicine.2021; 10(5): 1115.     CrossRef
• Ethnic disparities in COVID-19 mortality in Mexico: A cross-sectional study based on national data
  Ismael Ibarra-Nava, Kathia G. Flores-Rodriguez, Violeta Ruiz-Herrera, Hilda C. Ochoa-Bayona, Alfonso Salinas-Zertuche, Magaly Padilla-Orozco, Raul G. Salazar-Montalvo, Mary Hamer Hodges
  PLOS ONE.2021; 16(3): e0239168.     CrossRef
• Association of Kidney Disease With Outcomes in COVID‐19: Results From the American Heart Association COVID‐19 Cardiovascular Disease Registry
  Anjali Rao, Sagar Ranka, Colby Ayers, Nicholas Hendren, Anna Rosenblatt, Heather M. Alger, Christine Rutan, Wally Omar, Rohan Khera, Kamal Gupta, Purav Mody, Christopher DeFilippi, Sandeep R. Das, S. Susan Hedayati, James A. de Lemos
  Journal of the American Heart Association.2021;[Epub]     CrossRef
• Risk Factors and Clinical Phenotypes Associated with Severity in Patients with COVID-19 in Northeast Mexico
  Francisco Javier García-Alvarado, Melisa Alejandra Muñoz-Hernández, Elida Moran Guel, Marisela del Rocío González-Martínez, Maritza Argelia Macías Corral, Héctor Alberto Delgado-Aguirre
  Vector-Borne and Zoonotic Diseases.2021; 21(9): 720.     CrossRef
• COVID‐19‐related deaths among women of reproductive age in Brazil: The burden of postpartum
  Roxana Knobel, Maíra L. S. Takemoto, Marcos Nakamura‐Pereira, Mariane O. Menezes, Vicente K. Borges, Leila Katz, Melania M. R. Amorim, Carla B. Andreucci
  International Journal of Gynecology & Obstetrics.2021; 155(1): 101.     CrossRef
• Autosomal Dominant Polycystic Kidney Disease Does Not Significantly Alter Major COVID-19 Outcomes among Veterans
  Xiangqin Cui, Julia W. Gallini, Christine L. Jasien, Michal Mrug
  Kidney360.2021; 2(6): 983.     CrossRef
• The Association of Asthma With COVID-19 Mortality: An Updated Meta-Analysis Based on Adjusted Effect Estimates
  Hongjie Hou, Jie Xu, Yang Li, Yadong Wang, Haiyan Yang
  The Journal of Allergy and Clinical Immunology: In Practice.2021; 9(11): 3944.     CrossRef
• Factors Associated With Severe COVID-19 Infection Among Persons of Different Ages Living in a Defined Midwestern US Population
  Jennifer L. St. Sauver, Guilherme S. Lopes, Walter A. Rocca, Kavita Prasad, Michelle R. Majerus, Andrew H. Limper, Debra J. Jacobson, Chun Fan, Robert M. Jacobson, Lila J. Rutten, Aaron D. Norman, Celine M. Vachon
  Mayo Clinic Proceedings.2021; 96(10): 2528.     CrossRef
• Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies
  Yahya Mahamat-Saleh, Thibault Fiolet, Mathieu Edouard Rebeaud, Matthieu Mulot, Anthony Guihur, Douae El Fatouhi, Nasser Laouali, Nathan Peiffer-Smadja, Dagfinn Aune, Gianluca Severi
  BMJ Open.2021; 11(10): e052777.     CrossRef
• Stability, Bifurcation, and a Pair of Conserved Quantities in a Simple Epidemic System with Reinfection for the Spread of Diseases Caused by Coronaviruses
  Jorge Fernando Camacho, Cruz Vargas-De-León, Hassan A. El Morshedy
  Discrete Dynamics in Nature and Society.2021; 2021: 1.     CrossRef
• Evaluation of Treatment Outcome for Pneumonia among Pre-Vaccinated COVID-19 Patients with/without Comorbidity in a Public Hospital in Bengkulu, Indonesia
  Diana Laila Ramatillah, Siew Hua Gan, Syed Azhar Syed Sulaiman, Dama Puja, Usman Abubakar, Ammar Ali Saleh Jaber, Stefanus Lukas, Nina Jusnita
  Vaccines.2021; 9(12): 1411.     CrossRef